Multidrug-resistant tuberculosis--can the tide be turned?
Despite continued control efforts, tuberculosis remains a leading cause of illness and death worldwide, with more cases today than at any previous time in history. Not only is there a global increase in the disease itself, there is a worrying rise in the number of cases resistant to the two principal antituberculosis drugs, isoniazid and rifampicin--so called multidrug resistance.
Zumla
A
A
Centre for Infectious Diseases and International Health, Royal Free and University College Medical School, Windeyer Institute for Medical Science, London, UK. a.zumla@ucl.ac.uk
Grange
J M
JM
D000995:Antitubercular Agents / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D014943:Global Health; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*
D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin